Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 4/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | PDE4A | P27815 | 3/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.47 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.47 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MGAM | O43451 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1223242 | 0.93 | PGR (0.55) | PGRPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL5499005 | 0.93 | PGR (0.55) | PGRLMNAPDE4APDE4BPDE4C | |
| SCHEMBL30954711 | 0.92 | PGR (0.47) | PGRLMNAPDE4APDE4BPDE4C | |
| SCHEMBL61843 | 0.91 | PGR (0.56) | PGRPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL22471385 | 0.90 | PDE4A (0.46) | PGRLMNAPDE4APDE4BPDE4C | |
| SCHEMBL2214049 | 0.90 | BACE1 (0.50) | PGRLMNAPDE4APDE4BPDE4C | |
| SCHEMBL2255855 | 0.89 | PGR (0.43) | PGRLMNAPDE4APDE4BPDE4C | |
| SCHEMBL5959179 | 0.89 | EPHX2 (0.59) | PGRLMNAPDE4APDE4BPDE4C | |
| SCHEMBL30898630 | 0.89 | EPHX2 (0.59) | PGRLMNAPDE4APDE4BPDE4C | |
| SCHEMBL27213020 | 0.88 | PGR (0.44) | PGRLMNAPDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026103873-A1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | 杭州百新生物医药科技有限公司 | 2026-05-21 | — | — | WO | disclosed |
| CN-122036699-A | THR-beta modulators and methods of use thereof | 阿利戈斯治疗公司 | 2026-05-15 | — | — | CN | disclosed |
| WO-2026098493-A1 | HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF | 江苏恒瑞医药股份有限公司 | 2026-05-15 | — | — | WO | disclosed |
| US-12617783-B2 | Heterocyclic GLP-1R agonists | BIOMEA FUSION, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| US-20260070902-A1 | SULFONYL DERIVATIVES AS CCR6 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2026-03-12 | — | — | US | disclosed |
| US-20250325677-A1 | STAT6 DEGRADERS | GILEAD SCIENCES INC (US) | 2025-10-23 | — | — | US | disclosed |
| US-20250320206-A1 | STAT6 DEGRADERS | GILEAD SCIENCES INC (US) | 2025-10-16 | — | — | US | disclosed |
| EP-4630402-A1 | SULFONYL DERIVATIVES AS CCR6 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2025-10-15 | — | — | EP | disclosed |
| US-20250304572-A1 | HETEROCYCLIC GLP-1R AGONISTS | BIOMEA FUSION, INC. | 2025-10-02 | — | — | US | disclosed |
| US-20250304561-A1 | MODULATORS OF THR-BETA AND METHODS OF USE THEREOF | ALIGOS THERAPEUTICS, INC. (US) | 2025-10-02 | — | — | US | disclosed |
| US-8084479-B2 | Thiazole compounds and methods of use | AMGEN INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-20090306085-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090270445-A1 | Thiazole compounds and methods of use | AMGEN INC. (US) | 2009-10-29 | — | — | US | disclosed |
| US-7514566-B2 | Thiazole compounds and methods of use | AMGEN, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| EP-1981884-A2 | THIAZOLE COMPOUNDS AS PROTEIN KINASE B (PKB) INHIBITORS | Amgen, Inc (US) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007084391-A2 | THIAZOLE COMPOUNDS AS PROTEIN KINASE B ( PKB) INHIBITORS | AMGEN INC. (US) | 2007-07-26 | — | — | WO | disclosed |
| US-20070173506-A1 | Thiazole compounds and methods of use | AMGEN INC. (US) | 2007-07-26 | — | — | US | disclosed |
| EP-1778222-A1 | PROGESTERONE RECEPTOR MODULATORS COMPRISING PYRROLE-OXINDOLE DERIVATIVES AND USES THEREOF | Wyeth (US) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006023107-A1 | PROGESTERONE RECEPTOR MODULATORS COMPRISING PYRROLE-OXINDOLE DERIVATIVES AND USES THEREOF | WYETH (US) | 2006-03-02 | — | — | WO | disclosed |
| US-20060030615-A1 | Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof | WYETH (US) | 2006-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304572-A1 | HETEROCYCLIC GLP-1R AGONISTS | GLP1R, GPR119, GIPR | PGR 2287/4885LMNA 3557/4885PDE4A 132/4885 |
| US-12617783-B2 | Heterocyclic GLP-1R agonists | GLP1R, GIPR, GPR119 | PGR 2079/4885LMNA 4045/4885PDE4A 345/4885 |
| US-20250304561-A1 | MODULATORS OF THR-BETA AND METHODS OF USE THEREOF | THRB, THRA, TRHR | PGR 820/4885LMNA 1883/4885PDE4A 1527/4885 |
| US-20250325677-A1 | STAT6 DEGRADERS | STAT6, STAT5B, STAT1 | PGR 1299/4885LMNA 2978/4885PDE4A 757/4885 |
| US-20260070902-A1 | SULFONYL DERIVATIVES AS CCR6 INHIBITORS | CCR6, CCR1, CCR4 | PGR 1774/4885LMNA 3447/4885PDE4A 2505/4885 |
| US-20090270445-A1 | Thiazole compounds and methods of use | MTOR, JAK2, TK2 | PGR 790/4885LMNA 1862/4885PDE4A 1827/4885 |
| US-20060030615-A1 | Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof | PGR, PGRMC2, PGRMC1 | PGR 1/4885LMNA 4489/4885PDE4A 1211/4885 |
| US-20070173506-A1 | Thiazole compounds and methods of use | MTOR, JAK2, PCK2 | PGR 1366/4885LMNA 3104/4885PDE4A 2193/4885 |
| US-20090306085-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | PGR 2892/4885LMNA 3795/4885PDE4A 1530/4885 |
| US-20250320206-A1 | STAT6 DEGRADERS | STAT6, STAT5B, STAT1 | PGR 1299/4885LMNA 2978/4885PDE4A 757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.